Liposome Formulation for Tuberculosis via Particle Size and Sucrose Optimization
Solution Overview
Problem
Current tuberculosis treatments, particularly for HIV-positive individuals, lack effective preventive and therapeutic options that provide long-lasting protection and are not prone to resistance, necessitating a more potent approach for prophylaxis and treatment of latent and active tuberculosis.
Innovation Solution
Development of liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain, optimized with a z-average particle size of 120 nm or less and containing sucrose, which enhances bioavailability and efficiency, combined with a liposome forming agent like soy lecithin and a tensioactive agent, to create a pharmaceutical composition for improved immunogenic response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional liposome-based agents are used for tuberculosis therapy, then the treatment can be administered, but the bioavailability and efficiency are insufficient
Solution Approach 1:
The patent changes the physical parameters of the liposome formulation by reducing the average particle size to 120 nm or less and optimizing sucrose content, which significantly improves bioavailability and efficiency compared to conventional liposome-based agents
Solution Approach 2:
The patent creates a composite liposome formulation combining cell wall fragments from Mycobacterium tuberculosis-complex strain with liposome forming agents and sucrose, achieving enhanced immunogenic response and therapeutic effectiveness
2Ease of manufacture
If cell wall fragments are obtained by homogenisation in water, then the preparation process is simple, but the immunological response is not induced
Solution Approach 1:
The patent introduces mineral oil as an intermediary substance during the homogenisation process of cell wall fragments. This intermediary enables the preparation to maintain simplicity while effectively inducing immunological response, as the mineral oil facilitates proper antigen presentation and immune cell activation
Solution Approach 2:
The patent creates a composite formulation combining cell wall fragments with mineral oil, where the combination produces synergistic effects that enhance immunogenicity while maintaining ease of manufacture through simple homogenisation
Data Source
AI summary
The invention provides liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain. It also provides a Mycobacterium tuberculosis-complex strain, fragments of which may be incorporated into selected embodiments of the liposome formulation. The invention further provides suspensions and pharmaceutical compositions comprising the liposome formulations. Furthermore, it discloses the use of the liposome formulations for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating or preventing tuberculosis, such as in preventing latent tuberculosis or in tuberculosis prophylaxis, optionally in combination therapy. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and efficiency.